News
DMAC
9.36
+3.54%
0.32
Weekly Report: what happened at DMAC last week (1026-1030)?
Weekly Report · 6d ago
DiaMedica Therapeutics Up Nearly 12%, on Track for Highest Close Since April 2021 -- Data Talk
Dow Jones · 10/28 17:38
Weekly Report: what happened at DMAC last week (1019-1023)?
Weekly Report · 10/26 09:29
DiaMedica announces enrollment of 200th patient in ReMEDy2 Phase 2/3 trial
TipRanks · 10/22 12:10
DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Benzinga · 10/22 12:03
DiaMedica Therapeutics provides update on FGR trial at KOL event
TipRanks · 10/19 12:16
Weekly Report: what happened at DMAC last week (1012-1016)?
Weekly Report · 10/19 09:29
Weekly Report: what happened at DMAC last week (1005-1009)?
Weekly Report · 10/12 09:31
Weekly Report: what happened at DMAC last week (0928-1002)?
Weekly Report · 10/05 09:31
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
Barchart · 09/30 07:30
Weekly Report: what happened at DMAC last week (0921-0925)?
Weekly Report · 09/28 09:29
H.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)
TipRanks · 09/22 09:45
Weekly Report: what happened at DMAC last week (0914-0918)?
Weekly Report · 09/21 09:29
Weekly Report: what happened at DMAC last week (0907-0911)?
Weekly Report · 09/14 09:31
Weekly Report: what happened at DMAC last week (0831-0904)?
Weekly Report · 09/07 09:28
Weekly Report: what happened at DMAC last week (0824-0828)?
Weekly Report · 08/31 09:31
Weekly Report: what happened at DMAC last week (0817-0821)?
Weekly Report · 08/24 09:31
Diamedica Therapeutics Balances Trial Momentum and Cash
TipRanks · 08/24 00:08
Weekly Report: what happened at DMAC last week (0810-0814)?
Weekly Report · 08/17 09:32
DM199: Encouraging Phase 2 Preeclampsia Data and Disease‑Modifying Potential Support Buy Rating and $12 Price Target
TipRanks · 08/11 16:15
More
Webull provides a variety of real-time DMAC stock news. You can receive the latest news about Diamedica Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.